Table 1.
Characteristics of randomized controlled trials included in this meta-analysis of trials of combination therapy versus monotherapy
| Studies | Combined therapy versus monotherapy | Medication dosage (mg/d) | Number of patients | Number of diabetes mellitus | Follow-up (months) | Mean age (years) | Mean eGFR (ml·min−1·1.73 m−2) | Mean BP (mmHg) | Jadad score |
|---|---|---|---|---|---|---|---|---|---|
| MacGregor et al., 2005[17] | Quinapril/amlodipine versus quninapril | 2.5+5 versus 5 | 45 | 0 | 48 | 50 | 20 | 149/88 | 3 |
| Nakagawa et al., 2011[13] | Candesartan/nifedipine versus candesartan | 8+20 versus 12 | 86 | NR | 4 | 58 | 67.7 | 157/98 | 3 |
| Petersen et al., 2001[16] | Spirapril/isradipine versus spirapril | 3+2.5 versus 6 | 40 | 9 | 21 | 58 | 31.4 | 151/88 | 3 |
| Ruggenenti et al., 2011[18] | Delapril/manidipine versus delapril | 30+10 versus 30 | 253 | 253 | 66 | 61 | 99.5 | 148/87 | 5 |
| Bakris et al., 1998[12] | Trandolapril/verapamil versus trandolapril | 2.9+219 versus 5.5 | 26 | 26 | 12 | 59 | 73 | 170/104 | 2 |
| Yilmaz et al., 2010[14] | Valsartan/amlodipine versus valsartan | 160+10 versus 160 | 73 | 73 | 3 | 48 | 112 | 150/82 | 1 |
| Herlitz et al., 2001[15] | Ramipril/felodipine versus ramipril | 5+5 versus 10 | 105 | 0 | 24 | 53 | 44 | 157/100 | 3 |
eGFR: Estimated glomerular filtration rate; BP: Blood pressure.